These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11220886)

  • 41. Socioeconomic impact of diabetic nephropathy: can we improve the outcome?
    Simeon G; Bakris GL
    J Hypertens Suppl; 1997 Mar; 15(2):S77-82. PubMed ID: 9218203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 43. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of angiotensin-converting-enzyme inhibition in patients with renal disease.
    Manley HJ
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S12-8. PubMed ID: 11030018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Renal effects of angiotensin-converting enzyme inhibitors and their therapeutic use in chronic terminal renal failure].
    Ritz E; Mann JF; Rambausek M
    Z Kardiol; 1988; 77 Suppl 3():57-60. PubMed ID: 2850688
    [No Abstract]   [Full Text] [Related]  

  • 46. ACE-inhibitors in severe hypertension.
    Herlitz H
    Scand J Urol Nephrol Suppl; 1984; 79():73-9. PubMed ID: 6089321
    [No Abstract]   [Full Text] [Related]  

  • 47. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
    Noble S; Sorkin EM
    Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comment on the contribution: Barnas, Ursula, Mayer, G.: Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Pieber TR; Brunner GA
    Wien Klin Wochenschr; 1995; 107(14):439-41. PubMed ID: 7668005
    [No Abstract]   [Full Text] [Related]  

  • 49. [Angiotensin-converting enzyme inhibition and progressing chronic nephropathy].
    Kamper AL; Strandgaard S
    Ugeskr Laeger; 1997 Nov; 159(48):7121-3. PubMed ID: 9417716
    [No Abstract]   [Full Text] [Related]  

  • 50. Angiotensin-converting enzyme inhibitors in diabetic nephropathy.
    Melchior WR; Bindlish V; Jaber LA
    Ann Pharmacother; 1993 Mar; 27(3):344-50. PubMed ID: 8384031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension.
    Reams GP; Lau A; Knaus V; Bauer JH
    J Clin Pharmacol; 1993 Apr; 33(4):348-53. PubMed ID: 8473550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.
    Wolfe MW; Saad RM
    Arch Intern Med; 1989 Jun; 149(6):1462-3. PubMed ID: 2543349
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical trials in progression of chronic renal failure.
    Striker GE; Klahr S
    Adv Intern Med; 1997; 42():555-95. PubMed ID: 9048130
    [No Abstract]   [Full Text] [Related]  

  • 54. Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure.
    Piccoli GB; Anania P; Biancone L; Mezza E; Vischi M; Jeantet A; Rabbia C; Savio D; Rossatto D; Gai M; Perin PC; Segoloni GP
    Nephrol Dial Transplant; 2001 May; 16(5):1084-5. PubMed ID: 11328932
    [No Abstract]   [Full Text] [Related]  

  • 55. Benazepril and the kidney: new indication. No better than the other ACE inhibitors.
    Prescrire Int; 1998 Dec; 7(38):174-6. PubMed ID: 10848048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research.
    Andreucci VE; Gallieni M; Brancaccio D
    J Nephrol; 1998; 11(3):105-9. PubMed ID: 9650118
    [No Abstract]   [Full Text] [Related]  

  • 57. Prevention of diabetic nephropathy.
    Materson BJ; Preston RA
    Hosp Pract (1995); 1997 Feb; 32(2):129-34, 139-40. PubMed ID: 9040425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin-converting enzyme inhibition: facts and fiction.
    Tamimi N; El Nahas AM
    Nephron; 2000 Apr; 84(4):299-304. PubMed ID: 10754405
    [No Abstract]   [Full Text] [Related]  

  • 59. [Advantages of long-term controlled stepwise therapy of arterial hypertension with the use of angiotensin converting enzyme inhibitor spirapril].
    Katel'nitskaia LI; Ivanchenko DN; Khansheva LA; Kholoshina LV; Glova SE; Pleskachev SA
    Kardiologiia; 2006; 46(3):35-8. PubMed ID: 16710253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of enalapril on progression of chronic renal insufficiency caused by diabetes and other etiologies: a 2-year study].
    Trbojević J; Stojimirović B
    Srp Arh Celok Lek; 2002; 130(3-4):87-90. PubMed ID: 12154520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.